AUTHORS
Haris Ali, MD, Aaron T. Gerds, MD, MS2, Ellen Ritchie, MD3, Srinivas Tantravahi, MD4, Jonathan How, MD5, Dominiek Mazure, MD6, Stefan Wickenhauser, MD7, Dominik Chraniuk, MD8, Michal Kwiatek, MD, PhD9, Eloise Beggiato, MD10, Martin Donchev, MD, PhD11, Zhanet Grudeva-Popova, MD, PhD, MHM12, Panagiotis Tsirigotis, MD, PhD13, Yi Chai14, Andrea Ellero, PhD15, Tomer Mark, MD16, Darko Miljkovic, MSc/PhD17, Reshma Rangwala, MD, PhD18, Amama Sadiq, MD, MPH19, Raajit K. Rampal, MD, PhD20
AFFILIATIONS
1 Queen's Medical Centre Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
2 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
3 Weill Cornell Medical College of Cornell University, New York, New York, United States
4 Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, United States
5 McGill University Health Center, Montreal, Quebec, Canada
6 University Hospital Ghent, Ghent, Belgium
7 CHU de Nîmes, Nîmes, France
8 Wojewódzki Szpital Zespolony w Toruniu, Torun, Poland
9 AidPort Clinical Trials Hospital, Skórzewo, Poland
10 University Hospital City of Health and Science of Turin - Hospital Molinette, Turin, Italy
11 Medical University Sofia, Sofia, Bulgaria, Specialized Hospital for Active Therapy of Hematological Diseases, Sofia, Bulgaria
12 Medical University of Plovdiv, St. George University Hospital, Plovdiv, Bulgaria
13 ATTIKON General University Hospital, National and Kapodistrian University of Athens, Athens, Greece
14 Karyopharm Therapeutics, Newton, Massachusetts, United States
15 Karyopharm Therapeutics, Newton, Massachusetts, United States
16 Karyopharm Therapeutics, Newton, Massachusetts, United States
17 Menarini Group, Zurich, Switzerland
18 Karyopharm Therapeutics, Newton, Massachusetts, United States
19 Karyopharm Therapeutics, Newton, Massachusetts, United States
20 Memorial Sloan-Kettering Cancer Center, New York, New York, United States
ABSTRACT
Background: Myelofibrosis (MF) is a myeloproliferative neoplasm driven by dysregulated JAK/STAT activity and inflammatory cytokine dysregulation. Current standard of care, including JAK inhibitors (JAKi), improves symptoms but achieves limited depth and durability of spleen volume reduction (SVR). Furthermore, thrombocytopenia, which is common in MF and associated with poor outcomes, limits dosing of ruxolitinib and by extension leads to reduced efficacy.
The Phase 3 SENTRY study (NCT04562389) showed that the combination of selinexor and ruxolitinib vs ruxolitinib in JAKi-naïve patients (pts) with MF demonstrated rapid, deep, and sustained spleen responses, similar improvements in symptoms, and a manageable safety profile. However, pts with MF and thrombocytopenia have limited therapeutic options. SENTRY findings support the rationale to explore selinexor monotherapy (same dosing as in SENTRY) in subpopulations with thrombocytopenia.
Aim: Present early findings from the Phase 2 study SENTRY2 on the first 19 pts in cohort 1 who completed 24 weeks of follow-up as of July 1, 2026, with results on all 29 pts available at time of presentation.
Methods: SENTRY2 (NCT05980806) is a multicenter, open-label, Phase 2 study evaluating the efficacy of selinexor monotherapy (cohort 1: 60 mg QW; n=29 per arm) in pts with JAKi-naïve MF and thrombocytopenia (platelet count ≥50x109/L). Optional ruxolitinib, pacritinib, or momelotinib treatment (based on platelet count) could be added for pts whose SVR from baseline is <10% at Week 12 or <35% at Week 24. Inclusion criteria include age ≥18 years, spleen volume ≥450 cm3, Dynamic International Prognostic Scoring System (DIPSS) Intermediate-1 or higher with symptoms, platelet counts ≥50x109/L, and ineligibility for stem cell transplantation. Select exclusion criteria include >10% blast in peripheral blood or bone marrow (BM) and previous treatment with JAKi for MF. Primary endpoint is spleen volume reduction ≥35% (SVR35) at Week 24. Key secondary endpoints are safety and absolute total symptom score (AbsTSS) at Week 24. Exploratory endpoints include changes in variant allele frequency (VAF) and BM fibrosis.
Results: As of July 1, 2026, 29 pts have been treated with selinexor (cohort 1), and median duration of treatment was 24 weeks. The median age was 66, 76% were male, median platelet count was 83x109/L (<100x109/L=65.5%), and median baseline hemoglobin level was 97 g/L. Fourteen pts were DIPSS Intermediate-2 (48%), and 5 were high risk (17%). Baseline mean spleen volume and AbsTSS with fatigue were 2533 cm3 and 25, respectively. At time of abstract submission, safety and efficacy data are available for n=19.
At Week 24, SVR35 was achieved in 31.6% of the intent-to-treat (ITT) (6/19) and 35.3% of the efficacy-evaluable (6/17) populations, with a mean percent change of -29.5%. SVR35 at any time among the ITT was 36.8% (7/19). Ten pts (52.6%) received optional add-on JAKi therapy; n=9 after Week 24 (47.4%). Only one pt who achieved SVR35 at Week 24 received prior add-on pacritinib.
Observed mean (standard deviation) change from baseline AbsTSS (excluding fatigue) at Week 24 was -2.7 (11.6) with add-on therapy and -1.9 (8.8) without add-on therapy. Twelve pts were evaluable for driver gene VAF changes; 83% (10/12) had a VAF decrease at Week 24, and 33% (4/12) had a VAF change ≥20% compared with screening visit. Central review of paired BM biopsies was evaluable for 10 pts at Week 24; 50% (5/10) showed ≥1 MF Grade improvement.
All 19 pts had at least one treatment-emergent adverse event (TEAE; Grade ≥3: 94.7%). TEAEs leading to dose reduction and discontinuation were 73.7% and 10.5%, respectively. Most common TEAEs were anemia (73.7%), thrombocytopenia (73.7%), and nausea (36.8%), including Grade ≥3 thrombocytopenia (68.4%) and anemia (57.9%). TEAEs leading to death occurred in 5.3% (n=1). Two pts with high-risk cytogenetics at baseline experienced confirmed leukemia transformation.
Updated efficacy and safety results in all 29 pts enrolled in cohort 1 will be reported at the time of presentation.
Conclusion: Early findings from the SENTRY2 study support the therapeutic relevance of XPO1 inhibition in MF. These findings suggest that selinexor monotherapy may provide clinically meaningful SVR at Week 24 in a predominantly thrombocytopenic pt population, supporting the potential utility and continued investigation of selinexor in MF, including in pts with thrombocytopenia.
DISCLOSURES
Raajit K. Rampal, MD, PhD: Protagonist - Honoraria; Sumitomo Dainippon - Honoraria; Karyopharm - Honoraria; Stemline Therapeutics - Research Funding; Ryvu - Research Funding; Incyte - Research Funding; Constellation - Research Funding; Zentalis - Research Funding; Merck - Research Funding; MorphoSys - Research Funding; BioMed Valley Discoveries - Research Funding; Sumitomo Dainippon - Consultancy (Includes expert testimony); Promedior - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); Constellation/Morphosys - Consultancy (Includes expert testimony); Protagonist - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); CTI - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Disc Medicines - Consultancy (Includes expert testimony); Kartos Therapeutics - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Roche Laboratories - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Jubilant - Consultancy (Includes expert testimony); Galecto - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Stemline Therapeutics - Consultancy (Includes expert testimony); MPN Research Foundation - Consultancy (Includes expert testimony); Blueprint - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Opna Bio - Consultancy (Includes expert testimony); BMS-Celgene - Consultancy (Includes expert testimony); Zentalis - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony); Cogent Bio - Consultancy (Includes expert testimony); Sobi Company - Consultancy (Includes expert testimony); Sierra Oncology/GSK - Consultancy (Includes expert testimony)